# Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

> **NCT02050854** · — · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Bipolar 1 Disorder
- Schizophrenia
- Mental Disorder
- Nervous System Disorders

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02050854
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02050854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02050854, "Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02050854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*